Primary peritoneal cancer Trials in New York, United States
Conditions / Primary peritoneal cancer / New York, United States
Clinical trials for Primary peritoneal cancer investigate a range of treatment strategies and patient populations.
22 total trials for this combination
Showing top 10 of 22 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | RECRUITING | PHASE1/PHASE2 |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | COMPLETED | PHASE2 |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | COMPLETED | PHASE1 |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | COMPLETED | PHASE2 |
| NCT01204749 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | COMPLETED | PHASE3 |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | RECRUITING | — |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | TERMINATED | PHASE3 |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | TERMINATED | PHASE3 |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | TERMINATED | PHASE2/PHASE3 |